.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Cerilliant
Express Scripts
Argus Health
Accenture
Novartis
Merck
Cipla
Cantor Fitzgerald

Generated: September 19, 2017

DrugPatentWatch Database Preview

EMBEDA Drug Profile

« Back to Dashboard

Which patents cover Embeda, and when can generic versions of Embeda launch?

Embeda is a drug marketed by Alpharma Pharms and is included in one NDA. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has forty-eight patent family members in twenty-two countries.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Summary for Tradename: EMBEDA

Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list7
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EMBEDA at DailyMed

Pharmacology for Tradename: EMBEDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-005Aug 13, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-004Aug 13, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-006Aug 13, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-005Aug 13, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-006Aug 13, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-004Aug 13, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-004Aug 13, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-004Aug 13, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-001Aug 13, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-002Aug 13, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EMBEDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-005Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-004Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-003Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-001Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-002Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-003Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-006Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-006Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-005Aug 13, 2009► Subscribe► Subscribe
Alpharma Pharms
EMBEDA
morphine sulfate; naltrexone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022321-004Aug 13, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EMBEDA

Drugname Dosage Strength RLD Submissiondate
morphine sulfate and naltrexone hydrochlorideExtended-release Capsules30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mgEmbeda5/28/2010
morphine sulfate and naltrexone hydrochlorideExtended-release Capsules60 mg/2.4 mgEmbeda5/25/2010
morphine sulfate and naltrexone hydrochlorideExtended-release Capsules100 mg/4 mgEmbeda5/3/2010

International Patent Family for Tradename: EMBEDA

Country Document Number Estimated Expiration
Slovenia2484346► Subscribe
South Korea20150029762► Subscribe
Cyprus1118077► Subscribe
New Zealand573757► Subscribe
Australia2007261451► Subscribe
European Patent Office2526932► Subscribe
European Patent Office2034975► Subscribe
Slovenia2034975► Subscribe
Israel195834► Subscribe
Australia2009251081► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Healthtrust
US Army
Medtronic
Merck
Accenture
Citi
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot